GlassScriptPhysician profile
Jamie Odom
NPI 1770116477
$1,526.97
in general payments reported to CMS, 2019-2025
11 companies · $40.32 in 2025
The $40.32 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $754 · 2022: $622 · 2023: $74.91 · 2024: $35.20 · 2025: $40.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $548.50 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $412.82 | 2021-2022 | |
| Inari Medical, INC. | $195.34 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $159.74 | 2021-2022 | |
| Amgen INC. | $78.35 | 2021-2023 | Repatha |
| Sage Therapeutics, LLC | $40.32 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $26.69 | 2021 | |
| Abbvie INC. | $21.75 | 2024 | |
| Daiichi Sankyo INC. | $18.09 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.45 | 2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Odom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.